TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05498857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular ephedrine
Description: Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intramuscular ephedrine
Description: Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
Study: NCT05967468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based, Internet-Based Cognitive Behavioral Therapy
Description: Family-based cognitive behavioral therapy employing internet-delivered modules and videos

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bibliotherapy, low therapist contact SPACE
Description: Parent-based bibliotherapy for treating anxiety disorders in youth
Study: NCT06788925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patients support with active thermic jacket
Description: The intervention Description is exactly the same, except that the patient will be given a ThermUp jacket
Study: NCT06183437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stopping Heart Failure Medication(s)
Description: This group will stop their heart failure medication(s) under the supervision of the study team.
Study: NCT06787586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATTO-1310
Description: ATTO-1310 Attobody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATTO-1310
Description: ATTO-1310 Attobody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATTO-1310
Description: ATTO-1310 Attobody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATTO-1310 Placebo
Description: Placebo preparation to match ATTO-1310 Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATTO-1310 Placebo
Description: Placebo preparation to match ATTO-1310 Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATTO-1310 Placebo
Description: Placebo preparation to match ATTO-1310 Dose
Study: NCT06788496

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Art-based Beauty Appreciation Intervention Program (Learning to See Beauty)
Description: The goals of the intervention program are to help individuals develop an aesthetic mindset, practice observation and appreciation skills, learn how to apply these skills to their day-to-day lives, practice emotion regulation with beauty, and incorporate more beauty into their lives. The program is designed to create a slow skill transfer from appreciation in art contexts to natural beauty and to everyday life. In the 14-day program, participants visit an art museum with guided audio, watch instructional videos about observing and appreciating beauty, and complete daily written or photo beauty journals that document the beauty they see. In addition, participants will watch video art showing how to find beauty in mundane objects, practice this in a beauty walk, and complete a planning session to include more beauty in their lives.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Observation Program (Learning to Observe Life)
Description: The active, matched control group will focus on developing pragmatic observation skills. Participants will be instructed to pay attention to and identify objects and elements in their surroundings without emphasizing their aesthetic value. For example, they should pay attention and count objects of the same colour they encounter, social behaviour, the people they pass on the street, or the types of buildings. The 14-day program includes a tourist trip with guided audio instruction, watching instructional videos about increasing observation skills and completing daily written or photo journals to document their observations. Further, participants will take an observation walk and plan to include more observation in their lives.
Study: NCT06790199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years® Helping Preschool Children with Autism program (IY-HPCA)
Description: The IY-HPCA® program is a face-to-face 6-session group-based intervention for preschool teachers of children aged 2-5 with ASD or language and communication difficulties. Sessions last 3 hours, are delivered weekly, and are led by two trained co-leaders who have experience working with children on the autism spectrum. The program covers three main topics: (1) language development, (2) social interactions, and (3) emotion literacy and self-regulation. Teachers learn about coaching language, imitation, sensory routines, social communication, use of pretend and puppet play, and self-regulation skills. Visual supports such as picture schedules, choice cards, command and feelings cards are used, and practices are tailored to children's communication and play level stages. The intervention is structured and includes role-playing techniques and video visualization.
Study: NCT06789445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OpCT-001
Description: Cell therapy product composed of photoreceptor precursor cells derived from human induced pluripotent stem cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OpCT-001
Description: Cell therapy product composed of photoreceptor precursor cells derived from human induced pluripotent stem cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OpCT-001
Description: Cell therapy product composed of photoreceptor precursor cells derived from human induced pluripotent stem cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OpCT-001
Description: Cell therapy product composed of photoreceptor precursor cells derived from human induced pluripotent stem cells.
Study: NCT06789029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perineural Dexamethasone
Description: Erector Spinae Plane Block with 0.2% Ropivacaine + 0.1mg/kg perineural Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous Dexamethasone
Description: Erector Spinae Plane Block with 0.2% Ropivacaine + 0.1mg/kg intravenous Dexamethasone
Study: NCT06789380

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Schema therapy
Description: Schema therapy (ST) is an evidence-based, fully manualized, specialist form of psychotherapy for personality disorders (Bamelis et al., 2014; Sempértegui et al., 2013; Arntz et al., 2022). Eligible programs must adhere to the minimum standards described in the evidence-based literature. ST is an integrative treatment method, originally rooted in cognitive theory, but with additional influences from Gestalt, psychodynamic, and experiential methods. Schema therapy programs may differ in intensity and duration, even at the same site, but must include a minimum of either 40 sessions and/or a duration of 12 to 24 months. In addition, in order to be eligible, a schema therapy program must be of higher intensity or longer duration than the generalist treatment (GIT-PD) offered at the same site.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mentalization-based treatment
Description: Mentalization-based treatment (MBT) is an evidence-based, fully manualized, specialist form of psychotherapy for personality disorders (Bateman \& Fonagy, 2008; Bateman \& Fonagy, 2009; Laurenssen et al., 2018; Juul et al., 2023). MBT is rooted in psychodynamic and attachment theory and aims to alter personality pathology by improving mentalizing and enhancing epistemic trust. Eligible programs must adhere to the minimum standards described in the evidence-based literature. MBT programs may differ in intensity and duration, even at the same site, but must include a minimum of either 40 sessions or a duration of 12 to 24 months. In additon, in order to be eligible, an MBT program must be of higher intensity or longer duration than the generalist treatment (GIT-PD) offered at the same site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline-informed treatment for personality disorders
Description: GIT-PD is a non-theoretical and non-methodological approach, based upon principles derived from common factors across evidence-based treatments for PD. GIT-PD has a flexible approach, enabling tailoring treatment to clinical needs of different types of patients. The treatment duration (start-end) is 12- 18 months. The treatment consists of three distinct phases. First, an assessment phase. Second, a modular treatment phase that offers either group or individual interventions. Third, a follow-up phase with limited treatment and focus on relapse prevention. In order to be eligible, GIT-PD should be less intensive than specialist psychotherapies offered in the control arm at the same location (i.e. MBT or ST). GIT-PD will not include evidence-based psychotherapy for personality disorders as described in previous RCTs.
Study: NCT06789991

Intervention type: DEVICE
Intervention: electromyography
Description: electromyographic activity of posterior oblique sling muscles will be measured

Intervention type: DEVICE
Intervention: electromyography
Description: electromyographic activity of posterior oblique sling muscles will be measured
Study: NCT06789276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supine position
Description: For patients scheduled for thoracoscopic surgery, thoracic paravertebral nerve block was performed under ultrasound guidance. After the injection of the drug, patients were positioned in either the supine position.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lateral decubitus position
Description: For patients scheduled for thoracoscopic surgery, thoracic paravertebral nerve block was performed under ultrasound guidance. After the injection of the drug, patients were positioned in the lateral decubitus position with the puncture side up.
Study: NCT05405088

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Pain Sensitive Questionnaire (PSQ) Corah's Dental Anxiety Scale (CDAS) Pain Catastrophizing Scale (PCS) Gender Eye color Hair color Blood group
Study: NCT06788366

Intervention type: DRUG
Intervention: Immunotherapy
Description: First-line regimen according to clinical practice

Intervention type: DRUG
Intervention: Immunotherapy
Description: First-line regimen according to clinical practice

Intervention type: DRUG
Intervention: Chemotherapy
Description: First-line regimen according to clinical practice
Study: NCT06789822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invitation to wear the smartwatch
Description: During a consultation with the psychiatrist, and after verifying the eligibility criteria, the patient will receive oral information about the study from the psychiatrist.
Study: NCT06789848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligufalimab
Description: Ligufalimab (AK117) 45 mg/kg IV over 120 minutes on Day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligufalimab
Description: Ligufalimab (AK117) 45 mg/kg IV over 120 minutes on Day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab (AK104) 10 mg/kg IV over 60 minuets at least 30 minutes after Ligufalimab on Day 1 every 3 weeks
Study: NCT05967468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation and Mentorship
Description: Relaxation based treatment
Study: NCT05166642

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandgrip Micro-Anchor Wound Closure
Description: This treatment group will utilize a suture closure technique for the deep dermal layers with Bandgrip being applied to the most superficial layer of the surgical incision

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture closure
Description: This treatment gourd will utilize suture closure technique for all layers of the surgical incision.
Study: NCT06278649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation and Guided Imagery
Description: Listening to a 15 minute relaxing pre-recorded script while laying down on an exercise mat
Study: NCT06789848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab (AK104) 10 mg/kg IV over 60 minuets at least 30 minutes after Ligufalimab on Day 1 every 3 weeks
Study: NCT06789263

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen hydrolyzed peptides
Description: Dissolved in flavoured water, single dose, 10 g

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Collagen hydrolyzed peptides
Description: Dissolved in flavoured water, single dose, 10 g

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose
Study: NCT06789458

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Professional mechanical plaque control
Description: thisThe first step in therapy is aimed at guiding behavior change by motivating the patient to undertake successful removal of supragingival dental biofilm and risk factor control and may include the following interventions:~* Interventions to improve the effectiveness of oral hygiene \[motivation, instructions (oral hygiene instructions, OHI)~* Professional mechanical plaque removal (PMPR), which includes the professional interventions aimed at removing supragingival plaque and calculus, as well as possible plaque-retentive factors that impair oral hygiene practices.~* Adjustment of faulty restoration and polishing~* The mechanical plaque control instructions for each patient include brushing and interdental cleaning techniques.
Study: NCT06148272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3971297
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3971297
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3971297
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3971297
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3971297
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3971297
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3971297 IV
Description: Administered IV
Study: NCT06790134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence device
Description: This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.
Study: NCT06784141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized Cognitive Behavior Therapy including third-wave
Description: In the personalized CBT, patients first complete 21 days of EMA with six assessment points daily to assess relevant processes of CPP models. Person-specific networks are estimated based on the EMA data. A network-based algorithm indicates the treatment target. The individual CBT modules are selected for the participants from a matching matrix that contains experts' module recommendations for specific treatment targets. After that, participants will receive one out of ten CBT modules addressing their treatment target. All treatment modules are based on evaluated treatment manuals and contain methods from Cognitive Behavior Therapy, Acceptance and Commitment Therapy or Mindful Selfcompassion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized Cognitive Behavior Therapy including third-wave
Description: In the personalized CBT, patients first complete 21 days of EMA with six assessment points daily to assess relevant processes of CPP models. Person-specific networks are estimated based on the EMA data. A network-based algorithm indicates the treatment target. The individual CBT modules are selected for the participants from a matching matrix that contains experts' module recommendations for specific treatment targets. After that, participants will receive one out of ten CBT modules addressing their treatment target. All treatment modules are based on evaluated treatment manuals and contain methods from Cognitive Behavior Therapy, Acceptance and Commitment Therapy or Mindful Selfcompassion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standardized Cognitive Behavior Therapy including third-wave
Description: The standardized CBT intervention is manual-based and contains five sessions of cognitive behavioral therapy. Based on the evaluated manual from EFFECT Back, a short version with 5 modules is used: attention control, relaxation techniques, behavioral activation, cognitive strategies, and consolidation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standardized Cognitive Behavior Therapy including third-wave
Description: The standardized CBT intervention is manual-based and contains five sessions of cognitive behavioral therapy. Based on the evaluated manual from EFFECT Back, a short version with 5 modules is used: attention control, relaxation techniques, behavioral activation, cognitive strategies, and consolidation.
Study: NCT06788470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC
Description: Intratracheal administration of umbilical cord-derived mesenchymal stem cells (MSCs).
Study: NCT06788275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (MIT)
Description: Patients allocated to the MIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will cycle continuously between the first and second ventilatory thresholds. The duration of each exercise session will be set according to the estimated energy expenditure of the long HIIT and short HIIT groups for each training block (energy expenditure-adjusted exercise sessions). All sessions will be supervised, and patients will be asked to avoid additional exercise. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (Short HIIT)
Description: Patients allocated to the Short HIIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-repetition sets of 1-min above the second ventilatory threshold. Patients will perform 1- and 3-min active recovery periods below the first ventilatory threshold between repetitions and sets, respectively. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
Study: NCT04629729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study: NCT06788275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (Long HIIT)
Description: Patients allocated to the Long HIIT will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-min high-intensity exercise bouts above the second ventilatory threshold separated by 4-min active recovery periods below the first ventilatory threshold. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
Study: NCT05587582

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete a survey
Study: NCT05113342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descartes-25
Description: allogeneic Mesenchymal Stem Cell product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descartes-25
Description: allogeneic Mesenchymal Stem Cell product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descartes-25
Description: allogeneic Mesenchymal Stem Cell product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descartes-25
Description: allogeneic Mesenchymal Stem Cell product.
Study: NCT06534086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) guided meditation therapy
Description: Tripp application on Meta Quest 3 VR headset

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) guided meditation therapy
Description: Tripp application on Meta Quest 3 VR headset

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: No VR, local anesthetic only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: No VR, local anesthetic only
Study: NCT06526975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamification exercise through a videogame
Description: Different exercises will be performed through a videogame.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamification exercise through a videogame
Description: Different exercises will be performed through a videogame.